All News

Found 297 articles

• Astria Therapeutics Names Chris Morabito Chief Medical Officer

  7/15/2022

  Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it has named Chris Morabito, M.D., as Chief Medical Officer.

• Fulcrum Phase 3 FSHD Clinical Trial using AMRA Medical's Whole-body MRI Measurements as a Key Secondary Endpoint

  7/13/2022

  REACH, a Phase 3 Clinical Trial of losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) utilizes AMRA's Muscle Fat Infiltration (MFI) as a secondary endpoint.

• Fulcrum Therapeutics Announces Departure of Chief Medical Officer

  7/11/2022

  Fulcrum Therapeutics, Inc. (Nasdaq: FULC), today announced that Chief Medical Officer, Christopher Morabito, M.D., will be leaving the company, effective July 13, 2022. Judith Dunn, Ph.D., President of Research and Development will provide interim leadership while the executive search for a new CMO is ongoing.

• AMRA Medical continues to advance FSHD research with whole-body MRI measurements

  7/5/2022

  AMRA Medical, a digital health company delivering a new standard in body composition analysis through rapid whole-body magnetic resonance imaging (MRI), today announced that the results of their Fulcrum-sponsored study highlighting the development and use of a whole-body MRI protocol for muscle analysis are now published in Neurology.

• Memic Announces Multiple Upcoming Presentations of Hominis® Surgical System at Society of Robotic and Digital Surgery 2022 Annual Meeting

  6/23/2022

  Memic Innovative Surgery Ltd. (Memic), a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that multiple abstracts detailing clinical data related to the Hominis® Surgical System for robotic-assisted transvaginal hysterectomy were accepted for presentation at the Society of Robotic and Digital Surgery (SRS) 2022 Annual Meeting.

• 

  In Tough Biotech Market, Third Rock Raises New $1.1B Fund

  6/15/2022

  Third Rock Ventures Fund VI, providing the company with $1.1 billion to invest in new life science companies. This brings Third Rock to a total of $3.8 billion across its venture funds.

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 10, 2022

  6/10/2022

  Fulcrum Therapeutics, Inc. announced that the Company granted nonstatutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

• Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial

  6/10/2022

  Fulcrum Therapeutics, Inc® (Nasdaq:FULC), a clinical stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced clinical proof-of-concept data from the ongoing Phase 1b trial of FTX-6058 for the treatment of sickle cell disease (SCD).

• Cureduchenne Strengthens Research and Investment Team With Addition of Vice President of Research and Partner of CureDuchenne Ventures

  5/13/2022

  CureDuchenne announced the promotion of Lianna Orlando, PhD, to Vice President of Research and the addition of Bradley Hodges, PhD as Partner of CureDuchenne Ventures.

• Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria

  5/12/2022

  Fulcrum Therapeutics, Inc® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will be presenting two posters at the European Hematology Association (EHA) Hybrid Congress which will take place June 9-12, 2022, in Vienna, Austria.

• Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

  5/9/2022

  Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2022.

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 06, 2022

  5/6/2022

  Fulcrum Therapeutics, Inc. announced that the Company granted nonstatutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

• Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference

  5/5/2022

  Fulcrum Therapeutics, Inc.® announced that management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference, on Thursday, May 12, 2022 at 11:20 a.m. PT.

• Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET

  5/2/2022

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that its first quarter 2022 financial results will be released on Monday, May 9, 2022 before the U.S. financial markets open.

• 

  BioSpace Movers & Shakers, April 8

  4/8/2022

  Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 08, 2022

  4/8/2022

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted nonstatutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

• PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development

  4/5/2022

  PepGen, Inc., a company developing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, announced that it has appointed Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development.

• Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting

  4/1/2022

  Fulcrum Therapeutics, Inc. today announced multiple oral and poster presentations on losmapimod for facioscapulohumeral muscular dystrophy (FSHD) at the American Academy of Neurology’s Annual Meeting, taking place April 2-7 in Seattle, WA.

• Exactech Celebrates 15 Years of Clinical Use: Equinoxe® Reverse Shoulder

  3/31/2022

  Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, commemorates the 15th anniversary of the launch of the Equinoxe® reverse prosthesis, a groundbreaking implant that has improved clinical outcomes and reduced complication rates1 relative to published meta-analyses2- and has served as the platform for several additional innovations in reverse shoulder arthroplasty.

• Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

  3/17/2022

  Fulcrum Therapeutics, Inc. today announced that it will host a Key Opinion Leader (KOL) meeting on Thursday, March 24, 2022 from 10:00am – 12:00pm ET to discuss the company’s program with losmapimod for facioscapulohumeral muscular dystrophy (FSHD).